Unlock unparalleled insights into patient responses with our standardized organoid platform. As the only holder of an exclusive license to provide preclinical oncology drug development and validation services using HUB Organoid Technology, our extensive biobank boasts over 730 well-characterized patient-derived organoid models, covering 22 cancer indications. By integrating high-throughput screening, co-culture systems, biomarker analysis, and cutting-edge imaging, we accelerate the development of effective therapies. Explore our organoid platform and elevate your research: https://hubs.la/Q03cfzj80
